Status:
COMPLETED
Comparison Of Outcome Of Treatment OF Topical 15%TCA VS Topical 0.05% Tretinoin In Treatment Of Acanthosis Nigricans
Lead Sponsor:
Jinnah Postgraduate Medical Centre
Conditions:
Acanthosis Nigricans
Eligibility:
All Genders
20-50 years
Phase:
NA
Brief Summary
Acanthosis nigricans (AN) is a dermatosis with aesthetic implications and is characterized by the focal or diffuse development of a velvety, hyperpigmented cutaneous thickening in intertriginous areas...
Detailed Description
Acanthosis nigricans is common, although exact prevalence depends upon the racial makeup of the population studied. Exact pathogenesis is unknown, elevated insulin concentrations result in direct and ...
Eligibility Criteria
Inclusion
- Patients who will present with acanthosis nigricans as per operational definition will be included in the study.
- Either gender.
- Age 20-50 years.
Exclusion
- Pregnancy.
- Breastfeeding.
- Patients with history of skin resurfacing by dermabrasion, chemical peels and facial laser within the preceding 9 months.
- Patients with history of hypersensitivity.
- Malignant Acanthosis Nigricans.
- Drug Induced Acanthosis Nigricans.
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 20 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06008327
Start Date
August 1 2022
End Date
June 20 2023
Last Update
August 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
JPMC
Karachi, Sindh, Pakistan